Work

Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.4615

Authors: M. I. Milowsky, M. Galsky, J. Lewin, C. P. Rozario, L. Owens, T. Marshall, D. Nanus, I. J. Webb, H. I. Scher

Institutions: Memorial Sloan Kettering Cancer Center, NewYork–Presbyterian Hospital, Takeda Oncology (United States)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589934703

Cites:

Cited by: 10

Related to: 10